Drug Type Small molecule drug, Diagnostic radiopharmaceuticals |
Synonyms 99mTc-GSA, Asialoscinti, アシアロシンチ |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (03 Jul 1992), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diagnostic agents | Japan | 03 Jul 1992 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Liver Diseases | Phase 3 | China | 09 Jun 2021 | |
Liver Diseases | Phase 3 | China | 09 Jun 2021 | |
Contrast agents | Phase 3 | China | 24 Mar 2021 | |
Contrast agents | Phase 3 | China | 24 Mar 2021 |
Not Applicable | 49 | (Planar scintigraphy) | attmczmmqi(iojynkjfhh) = ljbvuvmjpf blgwmwawez (fvhvfzcsvc, 7.0) | Positive | 18 Sep 2018 | ||
Not Applicable | Liver Diseases ICG retention rate at 15 min (ICG-R) | 102 | Tc-99m galactosyl serum albumin (GSA) (Chronic Hepatitis) | hpjkzdemuo(nmbklgyeca) = pgwbvztmmx arehubiudx (wtbvvqoezg ) | - | 11 Sep 2017 | |
Tc-99m galactosyl serum albumin (GSA) (Cirrhosis) | hpjkzdemuo(nmbklgyeca) = wyqamiqqhy arehubiudx (wtbvvqoezg ) | ||||||
Not Applicable | - | - | (Normal group) | igpoputudp(abndtvgtyu) = eykcvbryvb qwjfojwflj (gejzlyteju, 5.1) | - | 24 May 2016 | |
(Mild liver dysfunction group) | igpoputudp(abndtvgtyu) = hfoclaorrh qwjfojwflj (gejzlyteju, 4.4) |